Interpretative Information

Human Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients. Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including maribavir, letermovir, cidofovir, ganciclovir, valganciclovir  and foscarnet. Additionally, letermovir is approved specifically for prophylactic use in hematopoietic stem cell transplant (HSCT) patients. Proper patient management requires rapid detection of resistance. Laboratory testing should be used to confirm the occurrence of drug resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management. The CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir sequencing assay is designed to detect identified mutations in the UL54, UL56 and UL97 genes of CMV. The use of genotypic sequencing offers a rapid turnaround time, a broad range of antiviral resistance information, and the ability to provide information concerning new drugs as they become available.